Paul A Schmeltzer1, Andrzej S Kosinski2, David E Kleiner3, Jay H Hoofnagle3, Andrew Stolz4, Robert J Fontana5, Mark W Russo1. 1. Division of Hepatology, Carolinas Medical Center, Charlotte, NC, USA. 2. Duke Clinical Research Institute, Duke University, Durham, NC, USA. 3. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. 4. Division of Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles, CA, USA. 5. Department of Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA.
Abstract
BACKGROUND & AIMS: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used and have been associated with hepatotoxicity. Studies of liver injury from NSAIDs have been retrospective and prospective data are lacking. The aim was to report the features and outcomes of the subjects with severe drug-induced liver injury from NSAIDS. METHODS: The U.S. Drug Induced Liver Injury Network is a prospective registry of idiosyncratic drug hepatotoxicity. All patients are evaluated in a standard fashion and followed up for at least 6 months. RESULTS: Of 1221 Drug Induced Liver Injury Network cases that were adjudicated, 30 cases were attributed to eight different NSAIDs. The mean age was 52 years old, 24 (80%) were women, and 21 (70%) were Caucasian. The mean latency was 67 days. Common signs and symptoms at presentation were nausea (73%), jaundice (67%) and dark urine (67%). Mean peak serum aspartate aminotransferase, alanine aminotransferase, total bilirubin and alkaline phosphatase were 898 U/L, 1060 U/L, 12.2 mg/dl and 326 U/L. The most common pattern of injury was hepatocellular (70%) and autoantibodies were detected in 33% of cases. Diclofenac, was the most frequently implicated NSAID (16/30 cases), and characterized by hepatocellular injury. Seventeen cases resulted in hospitalization or prolongation of hospitalization and one patient died from complications of Stevens-Johnson syndrome because of diclofenac. CONCLUSIONS: Hepatocellular injury is the most common pattern seen with NSAID hepatotoxicity, and diclofenac is the most frequently implicated agent. Given the number of NSAID alternatives, diclofenac should be reserved for patients who fail other NSAIDs and a high level of suspicion for hepatotoxicity should be maintained.
BACKGROUND & AIMS: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used and have been associated with hepatotoxicity. Studies of liver injury from NSAIDs have been retrospective and prospective data are lacking. The aim was to report the features and outcomes of the subjects with severe drug-induced liver injury from NSAIDS. METHODS: The U.S. Drug Induced Liver Injury Network is a prospective registry of idiosyncratic drug hepatotoxicity. All patients are evaluated in a standard fashion and followed up for at least 6 months. RESULTS: Of 1221 Drug Induced Liver Injury Network cases that were adjudicated, 30 cases were attributed to eight different NSAIDs. The mean age was 52 years old, 24 (80%) were women, and 21 (70%) were Caucasian. The mean latency was 67 days. Common signs and symptoms at presentation were nausea (73%), jaundice (67%) and dark urine (67%). Mean peak serum aspartate aminotransferase, alanine aminotransferase, total bilirubin and alkaline phosphatase were 898 U/L, 1060 U/L, 12.2 mg/dl and 326 U/L. The most common pattern of injury was hepatocellular (70%) and autoantibodies were detected in 33% of cases. Diclofenac, was the most frequently implicated NSAID (16/30 cases), and characterized by hepatocellular injury. Seventeen cases resulted in hospitalization or prolongation of hospitalization and one patient died from complications of Stevens-Johnson syndrome because of diclofenac. CONCLUSIONS:Hepatocellular injury is the most common pattern seen with NSAID hepatotoxicity, and diclofenac is the most frequently implicated agent. Given the number of NSAID alternatives, diclofenac should be reserved for patients who fail other NSAIDs and a high level of suspicion for hepatotoxicity should be maintained.
Authors: Ann K Daly; Guruprasad P Aithal; Julian B S Leathart; Richard A Swainsbury; Tarana Singh Dang; Christopher P Day Journal: Gastroenterology Date: 2006-11-17 Impact factor: 22.682
Authors: Loren Laine; Lawrence Goldkind; Sean P Curtis; Laurine G Connors; Zhang Yanqiong; Christoper P Cannon Journal: Am J Gastroenterol Date: 2009-01-27 Impact factor: 10.864
Authors: Thomas J Urban; Yufeng Shen; Andrew Stolz; Naga Chalasani; Robert J Fontana; James Rochon; Dongliang Ge; Kevin V Shianna; Ann K Daly; M Isabel Lucena; Matthew R Nelson; Mariam Molokhia; Guruprasad P Aithal; Aris Floratos; Itsik Pe'er; Jose Serrano; Herbert Bonkovsky; Timothy J Davern; William M Lee; Victor J Navarro; Jayant A Talwalkar; David B Goldstein; Paul B Watkins Journal: Pharmacogenet Genomics Date: 2012-11 Impact factor: 2.089
Authors: Francisco J de Abajo; Dolores Montero; Mariano Madurga; Luis A García Rodríguez Journal: Br J Clin Pharmacol Date: 2004-07 Impact factor: 4.335
Authors: Herson Antonio González-Ponce; Ana Rosa Rincón-Sánchez; Fernando Jaramillo-Juárez; Han Moshage Journal: Nutrients Date: 2018-01-24 Impact factor: 5.717
Authors: Diana Dragoi; Andreas Benesic; Garwin Pichler; Nils A Kulak; Harald S Bartsch; Alexander L Gerbes Journal: Front Pharmacol Date: 2018-07-04 Impact factor: 5.810
Authors: Karin Hedenmalm; Alexandra Pacurariu; Jim Slattery; Xavier Kurz; Gianmario Candore; Rob Flynn Journal: Drug Saf Date: 2021-07-17 Impact factor: 5.606